{
    "organizations": [],
    "uuid": "49c1f34e50a6192d0987ba99a6b8196467fcd780",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dar-bioscience-enters-into-agreeme/brief-dar-bioscience-enters-into-agreement-to-acquire-product-to-address-vulvar-and-vaginal-atrophy-in-hormone-receptor-positive-breast-cancer-patients-idUSASC0A01X",
    "ord_in_thread": 0,
    "title": "Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone Receptor-Positive Breast Cancer Patients",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 7 (Reuters) - Dare Bioscience Inc:\n* DARÉ BIOSCIENCE, INC. ENTERS INTO AGREEMENT TO ACQUIRE PRODUCT TO ADDRESS VULVAR AND VAGINAL ATROPHY IN HORMONE RECEPTOR-POSITIVE BREAST CANCER PATIENTS\n* DARE BIOSCIENCE INC - DARÉ HAS ENTERED INTO AGREEMENT TO SECURE RIGHTS, CURRENTLY OWNED BY PEAR TREE, TO DEVELOP PT-101 Source text for Eikon:\nOur ",
    "published": "2018-05-07T20:10:00.000+03:00",
    "crawled": "2018-05-08T16:52:22.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "dare",
        "bioscience",
        "inc",
        "daré",
        "bioscience",
        "enters",
        "agreement",
        "acquire",
        "product",
        "address",
        "vulvar",
        "vaginal",
        "atrophy",
        "hormone",
        "breast",
        "cancer",
        "patient",
        "dare",
        "bioscience",
        "inc",
        "daré",
        "entered",
        "agreement",
        "secure",
        "right",
        "currently",
        "owned",
        "pear",
        "tree",
        "develop",
        "source",
        "text",
        "eikon"
    ]
}